Structure and mechanism of the human CTDNEP1-NEP1R1 membrane protein phosphatase complex necessary to maintain ER membrane morphology.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
28 May 2024
Historique:
medline: 22 5 2024
pubmed: 22 5 2024
entrez: 22 5 2024
Statut: ppublish

Résumé

C-terminal Domain Nuclear Envelope Phosphatase 1 (CTDNEP1) is a noncanonical protein serine/threonine phosphatase that has a conserved role in regulating ER membrane biogenesis. Inactivating mutations in CTDNEP1 correlate with the development of medulloblastoma, an aggressive childhood cancer. The transmembrane protein Nuclear Envelope Phosphatase 1 Regulatory Subunit 1 (NEP1R1) binds CTDNEP1, but the molecular details by which NEP1R1 regulates CTDNEP1 function are unclear. Here, we find that knockdown of NEP1R1 generates identical phenotypes to reported loss of CTDNEP1 in mammalian cells, establishing CTDNEP1-NEP1R1 as an evolutionarily conserved membrane protein phosphatase complex that restricts ER expansion. Mechanistically, NEP1R1 acts as an activating regulatory subunit that directly binds and increases the phosphatase activity of CTDNEP1. By defining a minimal NEP1R1 domain sufficient to activate CTDNEP1, we determine high-resolution crystal structures of the CTDNEP1-NEP1R1 complex bound to a peptide sequence acting as a pseudosubstrate. Structurally, NEP1R1 engages CTDNEP1 at a site distant from the active site to stabilize and allosterically activate CTDNEP1. Substrate recognition is facilitated by a conserved Arg residue in CTDNEP1 that binds and orients the substrate peptide in the active site. Together, this reveals mechanisms for how NEP1R1 regulates CTDNEP1 and explains how cancer-associated mutations inactivate CTDNEP1.

Identifiants

pubmed: 38776370
doi: 10.1073/pnas.2321167121
doi:

Substances chimiques

Phosphoprotein Phosphatases EC 3.1.3.16
Membrane Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2321167121

Subventions

Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : R35GM128666
Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : R01GM131004
Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : T32GM722345
Organisme : Alfred P. Sloan Foundation (APSF)
ID : na

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Shujuan Gao (S)

Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794.

Jake W Carrasquillo Rodríguez (JW)

Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06511.

Shirin Bahmanyar (S)

Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06511.

Michael V Airola (MV)

Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH